Zobrazeno 1 - 10
of 1 288
pro vyhledávání: '"Dallob, A."'
Autor:
Ronald C Hendrickson, Anita Y H Lee, Qinghua Song, Andy Liaw, Matt Wiener, Cloud P Paweletz, Jeffrey L Seeburger, Jenny Li, Fanyu Meng, Ekaterina G Deyanova, Matthew T Mazur, Robert E Settlage, Xuemei Zhao, Katie Southwick, Yi Du, Dan Holder, Jeffrey R Sachs, Omar F Laterza, Aimee Dallob, Derek L Chappell, Karen Snyder, Vijay Modur, Elizabeth King, Catharine Joachim, Andrey Y Bondarenko, Mark Shearman, Keith A Soper, A David Smith, William Z Potter, Ken S Koblan, Alan B Sachs, Nathan A Yates
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135365 (2015)
Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in medicine. Current trends suggest that biomarkers reflective of AD neuropathology and modifiable by treatment would provide supportive evidence for disease modificati
Externí odkaz:
https://doaj.org/article/9acb46913f794a2a8b1b2a7a679cc6a4
Autor:
Dallob, Aimee1 (AUTHOR), Luo, Wen-Lin1 (AUTHOR), Luk, Julie Mabalot1 (AUTHOR), Ratcliffe, Lisa1 (AUTHOR), Johnson-Levonas, Amy O.1 (AUTHOR), Schwartz, Jules I.1 (AUTHOR), Dishy, Victor2 (AUTHOR), Kraft, Walter K.3 (AUTHOR), De Hoon, Jan N.4 (AUTHOR), Van Hecken, Anne4 (AUTHOR), De Lepeleire, Inge5 (AUTHOR), Radziszewski, Waldemar1 (AUTHOR), Wagner, John A.1 (AUTHOR), Lai, Eseng1 (AUTHOR) eseng_lai@merck.com
Publikováno v:
Platelets. Nov2011, Vol. 22 Issue 7, p495-503. 9p. 5 Charts, 4 Graphs.
Autor:
Daniel J. Holder, Jeffrey L. Seeburger, C Joachim, Mary J. Savage, A. David Smith, Marc Combrinck, Vijay Modur, Karen Snyder, William Z. Potter, Michael Tanen, Derek L Chappell, Adam J. Simon, Omar F Laterza, Mary Flynn, Gordon K. Wilcock, Aimee Dallob
Publikováno v:
Journal of Alzheimer's Disease. 44:525-539
Cerebrospinal fluid (CSF) amyloid-β (Aβ) and tau have been studied as markers of Alzheimer's disease (AD). Combined Aβ42 and t-tau distinguishes AD from healthy controls with a sensitivity and specificity (sens/spec) near 89% across studies. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e11086d3820f96774e32cc9a2d0e48c1
https://doi.org/10.3233/jad-141725
https://doi.org/10.3233/jad-141725
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia
Autor:
Drake, Lynn, Hordinsky, Maria, Fiedler, Virginia, Swinehart, James, Unger, Walter P., Cotterill, Paul C., Thiboutot, Diane M., Lowe, Nicholas, Jacobson, Coleman, Whiting, David, Stieglitz, Sam, Kraus, Stephen J., Griffin, Edmond I., Weiss, Darryl, Carrington, Patrick, Gencheff, Christopher, Cole, Gary W., Pariser, David M., Epstein, Edwin S., Tanaka, Wesley, Dallob, Aimée, Vandormael, Kristel, Geissler, Lori, Waldsteicher, Joanne
Publikováno v:
In Journal of the American Academy of Dermatology 1999 41(4):550-554
Autor:
Lisa Ratcliffe, Amy O. Johnson-Levonas, Wen-Lin Luo, Jules I. Schwartz, Jan de Hoon, Victor Dishy, Eseng Lai, Julie Mabalot Luk, John A. Wagner, Anne Van Hecken, Waldemar Radziszewski, Walter K. Kraft, Aimee Dallob, Inge De Lepeleire
Publikováno v:
Platelets. 22:495-503
Laropiprant (LRPT) is being developed in combination with Merck's extended-release niacin (ERN) formulation for the treatment of dyslipidemia. LRPT, an antagonist of the prostaglandin PGD2 receptor DP1, reduces flushing symptoms associated with ERN.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94880ac79925cac8bcf858465a5ad9ff
https://doi.org/10.3109/09537104.2011.565433
https://doi.org/10.3109/09537104.2011.565433
Autor:
de Freitas, Juliano Tiburcio1 (AUTHOR), Thakur, Varsha1 (AUTHOR), LaPorte, Kathryn M.2 (AUTHOR), Thakur, Vijay S.3 (AUTHOR), Flores, Brian1 (AUTHOR), Caicedo, Valentina1 (AUTHOR), Ajaegbu, Chioma G. E.1 (AUTHOR), Ingrasci, Giuseppe1 (AUTHOR), Lipman, Zoe M.1 (AUTHOR), Zhang, Keman4 (AUTHOR), Qiu, Hong4 (AUTHOR), Malek, Thomas R.2 (AUTHOR), Bedogni, Barbara1 (AUTHOR) bxb602@miami.edu
Publikováno v:
Journal of Experimental & Clinical Cancer Research (17569966). 11/4/2024, Vol. 43 Issue 1, p1-14. 14p.
Autor:
Deborah Hilliard, Jules I. Schwartz, Derek L Chappell, Karen Snyder, Omar F Laterza, Patrick Larson, Jutta Miller, Mary Flynn, John A. Wagner, Jane Royalty, Aimee Dallob, Paul F. Cavanaugh
Publikováno v:
The Journal of Clinical Pharmacology. 48:745-754
We determined cyclo-oxygenase-1 and cyclo-oxygenase-2 inhibition in healthy middle-aged subjects (41-65 years) randomly assigned to four 7-day treatment sequences of etoricoxib 90 mg every day, celecoxib 200 mg twice a day, diclofenac 75 mg twice a d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5cb6ad034ecc121a79249ee904f1db4
https://doi.org/10.1177/0091270008317590
https://doi.org/10.1177/0091270008317590
Autor:
Xuemei Zhao, Jenny J. Li, Yi Du, Jeffrey L. Seeburger, C Joachim, Ronald C. Hendrickson, Andy Liaw, Andrey Bondarenko, Fanyu Meng, Derek L Chappell, Anita Y. H. Lee, Keith A. Soper, William Z. Potter, Mark S. Shearman, Matt Wiener, Nathan A. Yates, Cloud P. Paweletz, Katie Southwick, Qinghua Song, Aimee Dallob, Matthew T. Mazur, Vijay Modur, Robert E. Settlage, E. King, A. David Smith, Omar F Laterza, Ken S. Koblan, Ekaterina G. Deyanova, Karen Snyder, Dan Holder, Jeffrey R. Sachs, Alan B. Sachs
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135365 (2015)
PLoS ONE
PLoS ONE
Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in medicine. Current trends suggest that biomarkers reflective of AD neuropathology and modifiable by treatment would provide supportive evidence for disease modificati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d33846e24a255c34791aa098968a0c1a
http://europepmc.org/articles/PMC4535975?pdf=render
http://europepmc.org/articles/PMC4535975?pdf=render
Autor:
Paul J. De Schepper, Christopher J. Hawkey, Peggy H. Wong, Keith Gottesdiener, Barry J. Gertz, John A. Wagner, Lisa DeTora, Nancy G. B. Agrawal, Aimee Dallob, Scott A. Waldman, Nicholas J. Wight, Howard E. Greenberg
Publikováno v:
Scopus-Elsevier
Etoricoxib is a potent selective COX-2 inhibitor in man. Ex vivo whole-blood assays assessed COX-2 inhibition after oral administration of etoricoxib in single (5-500 mg) and multiple (25-150 mg) once-daily doses to healthy human subjects. A separate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdc480df0747abcef4cfecfb8fbee669
https://doi.org/10.1177/0091270003043006003
https://doi.org/10.1177/0091270003043006003
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia
Autor:
Paul C. Cotterill, Joanne Waldsteicher, Gary W. Cole, Edwin S. Epstein, Walter P. Unger, Coleman Jacobson, Sam Stieglitz, David M. Pariser, Maria K. Hordinsky, Edmond I. Griffin, Diane Thiboutot, Christopher Gencheff, Patrick R. Carrington, James M. Swinehart, Stephen J. Kraus, Wesley Tanaka, David A. Whiting, Virginia C. Fiedler, Nicholas J. Lowe, Lori A. Geissler, Lynn A. Drake, Kristel Vandormael, Darryl Weiss, Aimee Dallob
Publikováno v:
Journal of the American Academy of Dermatology. 41:550-554
Data suggest that androgenetic alopecia is a process dependent on dihydrotestosterone (DHT) and type 2 5alpha-reductase. Finasteride is a type 2 5alpha-reductase inhibitor that has been shown to slow further hair loss and improve hair growth in men w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d19c61c6e2f4451461de2dcbe22e770
https://doi.org/10.1016/s0190-9622(99)80051-6
https://doi.org/10.1016/s0190-9622(99)80051-6